Memantin v terapii dementsii
- Authors: Anikina M.A1, Vasenina E.E1, Levin O.S1
-
Affiliations:
- ГБОУ ДПО РМАПО, Москва
- Issue: Vol 15, No 2 (2013)
- Pages: 95-100
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/93884
- ID: 93884
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
M. A Anikina
ГБОУ ДПО РМАПО, МоскваКафедра неврологии ГБОУ ДПО РМАПО
E. E Vasenina
ГБОУ ДПО РМАПО, МоскваКафедра неврологии ГБОУ ДПО РМАПО
O. S Levin
ГБОУ ДПО РМАПО, МоскваКафедра неврологии ГБОУ ДПО РМАПО
References
- Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2003.
- Дамулин И.В. Сосудистая деменция и болезнь Альцгеймера. М., 2002.
- Левин О.С. Алгоритмы диагностики и лечения деменции. М., 2012.
- Левин О.С. Деменция с тельцами Леви. М., 2006.
- Одинак М.М., Литвиненко И.В., Емелин А.Ю. Открытое сравнительное исследование эффективности мемантина в терапии посттравматических когнитивных расстройств. Неврологич. журн. 2005; 6: 32–7.
- Яхно Н.Н. Актуальные вопросы нейрогериатрии. В кн.: Достижения в нейрогериатрии. М., 1995; с. 9–27.
- Aupperle P.M., Tariot P.N., Safirstein B. et al. Long - term safety and efficacy of memantine treatment in moderate to severe Alzheimer’s disease. Eur J Neurology 2007; 14 (1): 1097.
- Cummings J.L., Frank J.C., Cherry D. et al. Guidelines for managing Alzheimer’s disease. Am Fam Physician 2002; 65: 2525–34.
- Cummings J.L. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer’s disease. Neurology 2005; 65 (3): 18–24.
- Cummings J.L., Schneider E, Tariot P. et al. Behavioral effects of memantine in Alzheimer’s disease patients receiving donepezil treatment. Neurology 2006; 67: 57–63.
- Cummings J.L., Grossberg G, Green P. et al. Review of the safety and tolerability of treatment for moderate to severe AD. Eur J Neurology 2007; 14 (1): 1090.
- Doody R.S., Stevens J.C., Beck R.N. et al. Practice parameter: management of dementia (an evidence - based review). Neurology 2001; 56: 1154–66.
- Doody R.S., Wirth Y, Schmitt F. et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geritr Cogn Disord 2004; 18: 227–32.
- Farlow M.R., Cummings J.L. Effective Pharmacologic Management of Alzheimer’s disease. Am J Med 2007; 120: 388–97.
- Francis P.T. Behavioral effects of memantine: understanding the pharmacological rationale. Eur J Neurology 2007; 14 (1): 2098.
- Gauthier S, Wirth Y, Mobius H.J. Effects of memantine on behavioral symptoms in Alzheimer disease patients. Int J Geriatr Psychiatry 2005; 20: 459–64.
- Gauthier S (ed.). Clinical diagnosis and management of Alzheimer’s disease. London. Inf Health Care 2007.
- Graham S, Resnick E.M., Tocco M. et al. Memantine is safe and effective in the treatment of moderate to severe Alzheimer’s disease: updated meta - analysis. Eur J Neurology 2007; 14 (1): 1096.
- Li L, Sengupta A, Haque N et al. Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 2004; 566: 261–9.
- Lyketos C.G., Colenda C.C., Beck C. et al. Position statement of AAGP regarding principles of care for patients with dementia resulting from Alzheimer's disease. Am J Geriatr Psychiatry 2006; 14: 561–73.
- Mendez M.F., Cummings J. Dementia. Philadelphia, Butterworth Heinemann 2003.
- Orgogozo J.M., Rigaud A.S., Stöffler A. et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300). Stroke 2002; 33: 1834–9.
- Parsons C.G., Danysz W, Quack G. Memantine is clinically well tolerated NMDA-receptor antagonist. Neuropharmacology 1999; 38: 735–67.
- Petersen K.A. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology 2007; 14 (1): 1107.
- Peskind E.R., Potkin S.G., Pomara N. et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry 2006; 14: 704–15.
- Reisberg B, Doody R, Stoffler A, Schmitt F et al. Memantine in moderate - to - severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41.
- Reisberg B, Doody R, Stoffler A et al. A 24-week open - label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol 2006; 63: 49–54.
- Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of mementine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9: 275–308.
- Scharre D.W. Galantamine with adjunctive memantine: combined effects on brain nicotinic acetylcholine receptors and NMDA receptors may improve Alzheimer’s disease symptomatology. J Clin Pharmacol 2006; 46: 6.
- Schmidt R, Ropele S, Ebenbauer B. et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology 2007; 14 (1): 2526.
- Sonkusare S.K., Kaul C.L., Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders – memantine, a new hope. Pharmacol Research 2005; 51: 1–17.
- Stoffler A, Wirth Y, Mobius H.J. Treatment of vascular dementia with memantine over one year. Eur J Neurology 2005; 12 (1): 2089.
- Tariot P.T., Farlow M.R., Grossberg G.R. et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial JAMA 2004; 291: 317–24.
- Tocco M, Resnick E.M., Graham S. et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology 2007; 14 (1): 1098.
- Waldemar G, Dubois B, Emre M. et al. Alzheimer’s disease and other disorders associated with dementia. R.Hughes et al. European handbook of neurological management. Oxford. Blackwell Publishing 2006; p. 266–98.
- Wilkinson D, Andersen H.F. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24: 138–45.
- Wilcock G, Möbius H.J., Stöffler A. A double - blind, placebo - controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002; 17: 297–305.
- Winblad B, Jones R, Wirth Y. et al. Memantine in moderate to severe Alzheimer’s disease: meta - analysis of randomized clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20–7.